GlassScriptPhysician profile
Frank Anthony Rich
NPI 1366419277
$6,681.90
in general payments reported to CMS, 2019-2025
28 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $802 · 2021: $1,576 · 2022: $1,363 · 2023: $543 · 2024: $707 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,164.54 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $998.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $583.76 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Amarin Pharma, INC. | $545.48 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $456.11 | 2021 | |
| Horizon Therapeutics Plc | $383.49 | 2021-2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $360.06 | 2022 | |
| Pfizer INC. | $346.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $241.63 | 2019-2023 | |
| Novo Nordisk INC | $212.87 | 2019-2023 | Wegovy |
| Esperion Therapeutics, INC. | $177.83 | 2020-2025 | Nexletol |
| Abbvie INC. | $154.50 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.26 | 2020-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $137.13 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Currax Pharmaceuticals LLC | $122.67 | 2021-2023 | Onzetra Xsail, Contrave |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $122.27 | 2019 | |
| Avanir Pharmaceuticals, INC. | $116.46 | 2019 | |
| Astellas Pharma US INC | $73.60 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $65.85 | 2019-2021 | |
| Orexo US, INC. | $63.15 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $37.77 | 2020 | |
| Glaxosmithkline, LLC. | $37.08 | 2023 | Trelegy Ellipta, Shingrix |
| Endo Pharmaceuticals INC. | $32.49 | 2021 | |
| Seqirus USA INC | $31.74 | 2025 | Flucelvax |
| Janssen Pharmaceuticals, INC | $20.65 | 2024 | Xarelto |
| Nevro Corp. | $19.33 | 2021 | |
| Sanofi Pasteur INC. | $19.24 | 2023 | |
| Axsome Therapeutics, INC. | $17.55 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.